MacroGenics, Inc. (MGNX)
Quick facts
| Ticker | MGNX (NASDAQ) |
|---|
Marketed products
- Hepatitis A vaccine · Immunology
Hepatitis A vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protection against infection.
Phase 3 pipeline
- Physician's choice of chemotherapy. · Oncology
This is a placeholder term referring to standard chemotherapy regimens selected by the treating physician, rather than a specific drug entity.
Phase 1 pipeline
- enoblituzumab plus ipilimumab
- Enoblituzumab Schedule 1
- Enoblituzumab Schedule 2
- MGC026 Dose Escalation
- MGC026 Dose for Expansion
- MGC028
- MGD007
- MGD010
- MGD024
- monoclonal antibody RAV12
- obrindatamab · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: